DLL3 and small cell lung carcinoma: Targeted radiotherapy using the radioimmunoconjugate[177Lu]Lu-DTPA-CHX-A-SC16—a lutetium-177-labeled DLL3 monoclonal antibody—demonstrates precise binding to DLL3 on SCLC cells, enabling localized radiation delivery while sparing healthy tissues, a breakthrough in precision oncology (105).